Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

ARRY 3.95 0.00 (0.00%)
price chart
3 Reasons to Watch Array Biopharma Inc.
Array's strength in development is their broad target screening methodology. Array has developed a proprietary kinase-inhibitor screening platform to generate new drug leads.
Why Oncotheryeon, Inc., OncoMed Pharmaceuticals, Inc., and Array BioPharma ...
What: Shares of Oncothyreon (NASDAQ: ONTY ) , a developmental biotech, climbed more than 13% today, while fellow biotech stocks OncoMed (NASDAQ: OMED ) and Array BioPharma (NASDAQ: ARRY ) roared higher by as much as 10% and 16.4%, ...
Puma Biotechnology Inc (NYSE:PBYI) Nearly Quadruples, Lifting Cancer ...  Markets Emerging
Related articles »  
Array BioPharma, Inc. (ARRY) Jumps: Stock Surges 10.7% Higher
Array BioPharma, Inc. (ARRY - Snapshot Report) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.
Stocks in the Spotlight- Array Biopharma Inc (NASDAQ:ARRY), Pacific Drilling ...
Manhattan, NY- 27 November, 2014 - (Techsonian) - Array Biopharma Inc (NASDAQ:ARRY) promulgated that its CEO, Ron Squarer, will speak at the following upcoming conferences.
Morning Briefing on Biotech Stocks - Arrowhead Research, Array BioPharma ...
On Tuesday, shares in Array BioPharma Inc. traded between $3.63 and $3.85 before ending the session 2.70% higher at $3.81. The stock reported a trading volume of 1.71 million shares, above its three months average volume of 1.27 million shares.
Related articles »  
Array BioPharma Inc.: Array BioPharma Reports Financial Results For The First ...
BOULDER, Colo., Nov. 4, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the first quarter of its fiscal year ending June 30, 2015.
Hot Stocks - RealPage , E*TRADE , Array BioPharma , Altera Corp , Catamaran ...  Markets Insider
Related articles »  
Array BioPharma Announces Drug Discovery Collaboration Agreement With ...
About Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Array BioPharma Collaborates with Biogen  Zacks.com
Array BioPharma strikes research pact with Biogen Idec  Denver Business Journal (blog)
Related articles »  
Disclosure on High Short Interest:Array Biopharma Inc , Sprint Corporation
Shares of Array Biopharma Inc (NASDAQ:ARRY) are trading at $3.9. The price is 35.7% off the 52-week high and 23.6% off the 52-week low.
Array BioPharma To Present At The Piper Jaffray And Oppenheimer 2014 ...  CNNMoney
Related articles »  
Array BioPharma To Present At The Stifel 2014 Healthcare And Jefferies 2014 ...
10, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, +2.11% today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences.
Watch List: Array Biopharma Inc (NASDAQ:ARRY), Physicians Realty Trust ...  Techsonian (press release)
Related articles »  
Array BioPharma Falls Despite Narrower-than-Expected Q4 Loss
Share price of Array BioPharma Inc. (ARRY - Snapshot Report) fell 5.1% after the company announced its fiscal fourth quarter results on Aug 12.